Business Description
XSpray Pharma AB
ISIN : SE0009973563
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.63 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.17 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -36.6 | |||||
3-Year EPS without NRI Growth Rate | -30.7 | |||||
3-Year FCF Growth Rate | -6.9 | |||||
3-Year Book Growth Rate | -10.1 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 66.27 | |||||
9-Day RSI | 67.36 | |||||
14-Day RSI | 64.51 | |||||
6-1 Month Momentum % | 30.69 | |||||
12-1 Month Momentum % | 40.33 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.67 | |||||
Quick Ratio | 3.5 | |||||
Cash Ratio | 3.32 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.9 | |||||
Shareholder Yield % | -20.69 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -34.45 | |||||
ROA % | -30.93 | |||||
ROIC % | -37.68 | |||||
ROC (Joel Greenblatt) % | -220.26 | |||||
ROCE % | -33.44 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 3.07 | |||||
Price-to-Tangible-Book | 9.49 | |||||
EV-to-EBIT | -8.93 | |||||
EV-to-Forward-EBIT | -30.43 | |||||
EV-to-EBITDA | -9.35 | |||||
EV-to-Forward-EBITDA | -30.43 | |||||
EV-to-Forward-Revenue | 4.37 | |||||
EV-to-FCF | -7.54 | |||||
Price-to-Net-Current-Asset-Value | 18.98 | |||||
Price-to-Net-Cash | 35.25 | |||||
Earnings Yield (Greenblatt) % | -11.2 | |||||
FCF Yield % | -12.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
XSpray Pharma AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.619 | ||
Beta | 0.25 | ||
Volatility % | 93.63 | ||
14-Day RSI | 64.51 | ||
14-Day ATR (€) | 0.260257 | ||
20-Day SMA (€) | 4.2965 | ||
12-1 Month Momentum % | 40.33 | ||
52-Week Range (€) | 2.76 - 7.51 | ||
Shares Outstanding (Mil) | 33.76 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
XSpray Pharma AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
XSpray Pharma AB Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
XSpray Pharma AB Frequently Asked Questions
What is XSpray Pharma AB(FRA:6XP)'s stock price today?
When is next earnings date of XSpray Pharma AB(FRA:6XP)?
Does XSpray Pharma AB(FRA:6XP) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |